Welcome to our dedicated page for Envista Holdings news (Ticker: NVST), a resource for investors and traders seeking the latest updates and insights on Envista Holdings stock.
Envista Holdings Corporation reports recurring developments as a global dental products company serving dental professionals through consumables, technologies, equipment and services. Its public updates center on quarterly results, core sales trends, adjusted earnings measures, cash flow, share repurchase activity and management presentations at healthcare conferences.
Company news also covers product and brand activity across DEXIS, Kerr, Nobel Biocare and Ormco, including dental implants, orthodontics, digital imaging, restorative and endodontic solutions. Recent product announcements include Kerr Dental's ZenSeal Pro with ZenSave Tips, reflecting Envista's focus on dental workflow, treatment technology and clinician-facing product commercialization.
Envista Holdings Corporation (NYSE: NVST) will participate in the Jefferies Virtual Dental Summit on February 24, 2022, from 6:00 – 6:45 AM PST. Investors can access recordings on the company's Investor Relations website under Events and Presentations. Envista is a global leader in dental products, offering a comprehensive portfolio that covers approximately 90% of dentists' clinical needs. The company emphasizes continuous improvement, innovation, and customer focus to enhance patient care and strengthen its market position.
Summary not available.
Envista Holdings Corporation (NYSE: NVST) reported a strong fourth quarter and full year 2021, following the divestiture of its KaVo Treatment Unit. Sales increased 5.8% to $651.8 million, with a core sales growth of 6.6% year-over-year. Full year core sales growth reached 29%. Fourth quarter net income was $42.5 million, with adjusted net income at $81.1 million, a 12% increase from the prior year. Looking ahead, Envista expects 2022 core growth of 6-8% and an adjusted EBITDA margin exceeding 20%, while indicating future guidance will be updated after the anticipated acquisition of Carestream Dental's IOS business.
Envista Holdings Corporation (NYSE: NVST) has renewed its partnership with the Vitaldent Group, a prominent Spanish Dental Service Organization. This agreement positions Envista as the preferred supplier for dental implants (Nobel Biocare) and clear aligners (Spark) for the next three years. Vitaldent, which has collaborated with Nobel Biocare since 2009, emphasizes the importance of innovative technology in providing quality dental care. The partnership aims to enhance clinical outcomes and patient satisfaction using advanced dental treatments.
Envista Holdings Corporation (NYSE: NVST) recently announced a five-year extension and expansion of its commercial relationship with Pacific Dental Services (PDS). This partnership will now include Envista's Spark clear aligners in addition to existing implant and imaging services. The collaboration aims to enhance implant treatment capabilities and improve diagnostic accuracy through advanced 3D imaging technology. Envista's SVP highlighted the commitment to clinical excellence, while PDS’s COO praised the partnership for enhancing patient care across over 850 supported practices.
Envista Holdings Corporation (NYSE: NVST) will report its fourth quarter 2021 financial results on February 9, 2022. A conference call to discuss these results will follow at 2:00 PM PT. Interested parties can access the call via phone or through a webcast on the company's website. A replay will be available post-presentation. Envista is a leading global dental products company, recognized for its extensive portfolio catering to 90% of dentists' clinical needs. The company focuses on continuous improvement and innovation in dental solutions.
Envista Holdings Corporation (NYSE: NVST) has announced a multi-year partnership with Pacific Dental Services (PDS) to enhance clinical image analysis through Assisted Intelligence (AI). This collaboration will utilize Envista's DTX Studio Clinic software across PDS-supported practices, enabling improved image sorting and interpretation. Both companies aim to revolutionize dental diagnostics by integrating AI and machine learning. Envista CEO Amir Aghdaei emphasized PDS as a true partner in innovation. The initiative seeks to enhance diagnosis, treatment planning, and ultimately health outcomes in dentistry.
Envista Holdings Corporation (NYSE: NVST) has successfully completed the sale of its KaVo Treatment Unit & Instrument business, receiving $317.3 million in cash upon closing. The total gross proceeds from the divestiture are projected to reach $383 million, which includes earnouts to be received by mid-2022. This strategic move allows Envista to allocate funds towards acquisitions and internal investments, enhancing its offerings to dental professionals. The Imaging business under the KaVo brand will remain with Envista.
Envista Holdings Corporation (NYSE: NVST) announced FDA clearance for its Nobel Biocare N1™ implant system, enhancing patient-centric solutions. This system integrates innovative features like the OsseoShaper™, which optimizes site preparation, improves patient comfort, and reduces noise compared to traditional methods. The N1™ also includes advanced surface treatments and is compatible with digital workflows via DTX Studio™. CEO Amir Aghdaei highlighted the growing demand for high-quality solutions in implantology. This development positions Envista to set new standards in dental implant treatment.
Envista Holdings Corporation (NYSE: NVST) announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 10, 2022, at 12:00 PM PST. The presentation will be virtual, and investors can access recordings on Envista's Investor Relations website under Events and Presentations. Envista is a prominent global dental products company, offering a comprehensive range of solutions to cater to dental professionals’ needs, which includes brands like Nobel Biocare and KaVo.